Biomarker cereblon for diagnosing hepatocellular carcinoma, and novel monoclonal antibody specific thereto

Abstract

Provided are the use of cereblon (CRBN) as a biomarker for diagnosis of hepatocellular carcinoma and novel monoclonal antibodies specific to CRBN. More specifically, provided are a composition and a kit for diagnosing or predicting the prognosis of hepatocellular carcinoma by using CRBN as a biomarker for diagnosis of hepatocellular carcinoma, an information providing method for diagnosing or predicting the prognosis of hepatocellular carcinoma, two novel monoclonal antibodies binding specifically to CRBN, and hybridoma cells producing the same. The expression level difference of CRBN protein allows patients with hepatocellular carcinoma to be diagnosed early and indicates better predictive capabilities than the presence or absence of microvascular invasion, which was an important factor in predicting a prognosis of hepatocellular carcinoma in prior art, and thus can be expected to be used as a diagnostic marker to diagnose hepatocellular carcinoma and to evaluate a prognosis after hepatic resection.

Dependencies are inferred from the claim text.